Compare stocks

BioArctic AB is a Swedish biopharmaceutical company focusing on developing treatments for central nervous system disorders. The company is notably engaged in the research and development of therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Founded in 2003, BioArctic collaborates with academic institutions and global pharmaceutical companies to advance its innovative approaches. The company is headquartered in Stockholm, Sweden, and leverages its strategic partnerships and scientific expertise to address unmet medical needs in its chosen field. BioArctic's competitive strengths include its proprietary technology platforms and strong intellectual property portfolio.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.